Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.